Asset Details
Do you wish to reserve the book?
Regorafenib in the treatment of metastatic colorectal cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Regorafenib in the treatment of metastatic colorectal cancer
Do you wish to request the book?
Regorafenib in the treatment of metastatic colorectal cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Regorafenib in the treatment of metastatic colorectal cancer
2018
Overview
Regorafenib is an orally available multikinase inhibitor, currently approved in metastatic chemorefractory colorectal cancer patients. The results of two large randomized Phase III trials are available, providing significant results in overall and progression-free survival in this situation. Its use requires a special attention regarding patient selection, dosing schedule and management of adverse events. Identifying patients who will tolerate and have benefit from regorafenib is a challenge for clinicians. Therapeutic monitoring (especially cfDNA), predictive biomarkers and specific perfusion-based imaging techniques will may be result in optimizing regorafenib treatment.
Publisher
Future Medicine Ltd
Subject
/ Antineoplastic Agents - adverse effects
/ Antineoplastic Agents - pharmacology
/ Antineoplastic Agents - therapeutic use
/ Antineoplastic Combined Chemotherapy Protocols - therapeutic use
/ Colorectal Neoplasms - drug therapy
/ Colorectal Neoplasms - pathology
/ Dose-Response Relationship, Drug
/ Humans
/ metastatic colorectal cancer
/ Mutation
/ Phenylurea Compounds - administration & dosage
/ Phenylurea Compounds - adverse effects
/ Phenylurea Compounds - pharmacology
/ Phenylurea Compounds - therapeutic use
/ Pyridines - administration & dosage
/ Studies
